Hiltonol®
Solid Tumors (e.g., Glioblastoma) in combination with vaccines/immunotherapy
Key Facts
About Oncovir
Oncovir is a privately held, clinical-phase biotech focused on a single, versatile asset: Hiltonol® (Poly ICLC). This stabilized double-stranded RNA compound acts as a broad immune activator, functioning as a 'danger signal' to stimulate the immune system against tumors and pathogens. The company's strategy involves advancing Hiltonol® through partnerships in various combination therapies for solid cancers and infectious diseases, positioning it as a potential backbone for next-generation immunotherapies and vaccine adjuvants. Oncovir operates as a lean organization, manufacturing GMP-grade material and seeking strategic collaborations to fund and execute clinical development.
View full company profileAbout Oncovir
Oncovir is a privately held, clinical-phase biotech focused on a single, versatile asset: Hiltonol® (Poly ICLC). This stabilized double-stranded RNA compound acts as a broad immune activator, functioning as a 'danger signal' to stimulate the immune system against tumors and pathogens. The company's strategy involves advancing Hiltonol® through partnerships in various combination therapies for solid cancers and infectious diseases, positioning it as a potential backbone for next-generation immunotherapies and vaccine adjuvants. Oncovir operates as a lean organization, manufacturing GMP-grade material and seeking strategic collaborations to fund and execute clinical development.
View full company profile